Strive, Inc. (ASST) wrapped up its acquisition of Semler Scientific this week, and the market's reaction was a collective shrug. Shares dipped on Friday even as the S&P 500 ticked higher and the Dow Jones wandered in the opposite direction. Sometimes good news is just priced in, or maybe investors are still trying to figure out what this healthcare-meets-Bitcoin hybrid is supposed to be.
The deal gives Strive a treasure chest of approximately 12,797.9 bitcoins, which puts the company at number 11 on the list of publicly traded corporate Bitcoin holders worldwide. That's a lot of digital gold sitting on the balance sheet, and it positions Strive as both a healthcare play and a proxy for Bitcoin (CRYPTO: BTC/USD) exposure. Whether that's genius or confusion depends on your investment philosophy.
New Leadership, New Strategy
Along with the bitcoin haul, Strive is bringing in fresh talent. Avik Roy has been tapped as Chief Strategy Officer, with a mandate to monetize Semler Scientific's existing operations and expand into early-disease detection products. It's a pivot that makes sense if you're trying to build real revenue streams alongside your cryptocurrency holdings.
Eric Semler, the former chairman of Semler Scientific, joins the board as an independent member, providing continuity and institutional knowledge. Meanwhile, Joe Burnett, who previously directed Bitcoin strategy for Semler Scientific, steps into the role of VP of Bitcoin Strategy at Strive. The company is clearly betting that combining healthcare innovation with Bitcoin treasury management can create something more valuable than either piece alone.
Technical Picture Shows Mixed Signals
The stock is trading 5.2% above its 20-day simple moving average, which sounds encouraging until you notice it's sitting 56.4% below its 100-day average. That's the technical analysis equivalent of saying things are looking up this week, but the year has been rough. Over the past 12 months, shares have climbed 102.98%, though they're currently hovering much closer to their 52-week lows than highs.
The RSI sits at 50.75, which is about as neutral as it gets. No strong momentum in either direction. The MACD, however, is above its signal line, suggesting bullish momentum might be building. Put those together and you get mixed signals—not exactly a clear roadmap for traders.
Key resistance sits at $1.00, while support holds around $0.50. The stock was trading at $0.96 at the time of publication, down 0.26% on Friday.
Earnings on the Horizon
Investors are eyeing the next earnings report scheduled for March 30, 2026. Analysts are forecasting earnings per share of negative $0.01, which would be a substantial improvement from negative $0.21 in the same quarter last year. Revenue is expected to hit $1.80 million, up dramatically from $0.21 million in the prior-year period.
The consensus among analysts is a Buy rating with an average price target of $1.50, suggesting they see upside from current levels even with the negative EPS projection.
The High-Flyer Risk
According to market data, Strive scores an 83 out of 100 on momentum metrics, indicating the stock is outperforming the broader market. Quality comes in at a solid 66 out of 100, suggesting the balance sheet is holding up reasonably well. But value? That's where things get dicey with a score of just 4 out of 100, meaning the stock is trading at a steep premium relative to peers.
This is what analysts call a "High-Flyer" setup. The momentum is real and the trend is strong, but the valuation is priced for perfection. If you're riding this wave, tight stop-losses aren't just recommended—they're probably essential. One stumble and that premium valuation could evaporate quickly.
The combination of healthcare operations, Bitcoin holdings, and expansion into early-disease detection creates an interesting, if complicated, investment thesis. Whether Strive can execute on both fronts simultaneously will determine if that 11th-place Bitcoin ranking translates into long-term shareholder value.
